GlassScriptPhysician profile
Sarah E French
NPI 1730386608
$4,083.68
in general payments reported to CMS, 2019-2025
45 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $512 · 2021: $562 · 2022: $418 · 2023: $251 · 2024: $725 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $570.78 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $361.19 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $345.88 | 2019-2025 | |
| Sequel Med Tech, LLC | $267.28 | 2025 | Twiist |
| Corcept Therapeutics | $252.05 | 2019-2025 | Korlym |
| Insulet Corporation | $202.29 | 2020-2025 | Omnipod |
| Abbott Laboratories | $175.42 | 2020-2025 | Freestyle Libre |
| Lilly USA, LLC | $152.31 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $150.49 | 2019-2025 | Airsupra, Breztri |
| Medtronic Minimed, INC. | $111.24 | 2020 | |
| Amgen INC. | $102.50 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbvie INC. | $96.66 | 2022-2025 | |
| Astellas Pharma US INC | $95.81 | 2020-2021 | |
| Ibsa Pharma INC. | $94.50 | 2023-2025 | Licart, Tirosint, Flector |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.30 | 2020-2024 | Xifaxan |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah French listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.